Geratherm Medical AG

XETRA GME.DE

Geratherm Medical AG EBITDA Margin for the year ending December 31, 2023: 18.76%

Geratherm Medical AG EBITDA Margin is 18.76% for the year ending December 31, 2023, a 43.94% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Geratherm Medical AG EBITDA Margin for the year ending December 31, 2022 was 13.04%, a 46.11% change year over year.
Geratherm Medical AG EBITDA Margin for the year ending December 31, 2021 was 8.92%, a -43.63% change year over year.
Geratherm Medical AG EBITDA Margin for the year ending December 31, 2020 was 15.83%, a 22.06% change year over year.
Geratherm Medical AG EBITDA Margin for the year ending December 31, 2019 was 12.97%, a 4.84% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

XETRA: GME.DE

Geratherm Medical AG

CEO	Mr. Christian Frick
IPO Date	July 3, 2000
Location	Germany
Headquarters	Fahrenheitstrasse 1
Employees	179
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Drugstores & Retail Pharmacies Hardware & Electronics Personal Care Pharmaceuticals Telehealth

Description

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.

Key trends

Past 5 years